Boston Scientific Corporation $BSX Holdings Lifted by Running Oak Capital LLC

Running Oak Capital LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 7.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 208,331 shares of the medical equipment provider’s stock after purchasing an additional 14,449 shares during the quarter. Running Oak Capital LLC’s holdings in Boston Scientific were worth $9,094,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BSX. Avantax Planning Partners Inc. raised its position in Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after buying an additional 201 shares during the last quarter. Natural Investments LLC boosted its holdings in shares of Boston Scientific by 1.3% in the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after acquiring an additional 206 shares during the last quarter. 180 Wealth Advisors LLC boosted its holdings in shares of Boston Scientific by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after acquiring an additional 223 shares during the last quarter. MGO One Seven LLC increased its stake in shares of Boston Scientific by 1.9% in the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after acquiring an additional 260 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of Boston Scientific by 1.4% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider’s stock worth $870,000 after acquiring an additional 268 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several recent research reports. The Goldman Sachs Group decreased their target price on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Evercore reduced their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. Wells Fargo & Company reduced their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. Jefferies Financial Group cut Boston Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the company from $60.00 to $46.00 in a report on Wednesday, October 28th. Finally, Deutsche Bank Aktiengesellschaft set a $48.00 target price on Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Stock Performance

BSX opened at $44.00 on Tuesday. The firm has a fifty day moving average price of $44.26 and a 200 day moving average price of $55.46. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The stock has a market cap of $63.78 billion, a P/E ratio of 18.64, a P/E/G ratio of 1.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the business earned $0.75 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. Equities research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.